| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Staphylococcal Enterotoxin B (SEB) and related superantigens. SEB Domain (152-161) TFA is a peptide that targets the transcytosis pathway of SEB and other staphylococcal enterotoxins. It binds to a conserved region on the toxin, blocking its transport across epithelial barriers. This inhibits the ability of SEB to be translocated across intestinal and other mucosal surfaces.
|
|---|---|
| ln Vitro |
In vitro, SEB Domain (152-161) TFA inhibits the transcytosis of several staphylococcal enterotoxins, including SEA, SEE, and TSST-1. The peptide targets a highly conserved region on these toxins that is critical for their transport across epithelial barriers. By blocking transcytosis, the peptide prevents toxin passage through the gut epithelium and other mucosal surfaces, potentially reducing systemic toxicity.
|
| ln Vivo |
In vivo efficacy data for SEB Domain (152-161) TFA are limited. As an inhibitor of staphylococcal enterotoxin transcytosis, the peptide is expected to reduce the systemic absorption of SEB and related toxins following oral or mucosal exposure. This could have therapeutic potential for preventing food poisoning and toxic shock syndrome caused by S. aureus toxins. Further in vivo studies are needed to evaluate its protective efficacy.
|
| Enzyme Assay |
Non-cell-based SEB binding assay: SEB toxin (0.5-5 ug/mL) is immobilized on ELISA plates. Increasing concentrations of SEB Domain (152-161) TFA (0-500 uM) are added and incubated for 1 hour at 37degC. Bound peptide is detected using biotinylated anti-SEB antibody followed by streptavidin-HRP and chemiluminescent substrate. Alternatively, binding affinity is measured by surface plasmon resonance (SPR) using immobilized SEB and flowing peptide concentrations (0-500 uM).
|
| Cell Assay |
Transcytosis inhibition assay: Epithelial cell monolayers (e.g., T84 or Caco-2) are grown on Transwell inserts until tight junctions are formed (TEER >500 omega·cm2). SEB toxin (1-10 ug/mL) is added to the apical chamber with or without SEB Domain (152-161) TFA (0-100 uM). After 2-4 hours of incubation at 37degC, basolateral medium is collected. Transcytosed SEB is quantified by ELISA. The percentage inhibition of transcytosis is calculated relative to toxin alone. Monolayer integrity is confirmed by 14C-mannitol flux or FITC-dextran permeability.
|
| Animal Protocol |
Mouse SEB challenge model (suggested): Female BALB/c mice (6-8 weeks old) are challenged intraperitoneally or intravenously with SEB toxin (5-25 ug/mouse) to induce toxic shock. SEB Domain (152-161) TFA is administered intravenously or intraperitoneally prior to or concurrently with SEB at doses of 1-50 mg/kg. Body temperature, weight, and survival are monitored over 24-96 hours. For transcytosis inhibition, a non-invasive oral challenge model with SEB followed by peptide administration by oral gavage may be used.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for SEB Domain (152-161) TFA are limited. As a synthetic peptide (MW 1273.35, TFA salt), it has limited oral bioavailability and short plasma half-life due to proteolytic degradation. For in vivo studies, administration is typically via intravenous or intraperitoneal injection. The peptide is water-soluble (50 mg/mL in water) and stable at -20degC for long-term storage. TFA salt enhances stability and solubility.
|
| Toxicity/Toxicokinetics |
Toxicity data for SEB Domain (152-161) TFA are limited. The peptide is intended for research use only and not for human therapeutic applications. As an inhibitor of SEB transcytosis, it is derived from a conserved domain of the toxin itself and is not expected to be toxic at relevant concentrations. However, standard safety precautions should be observed during handling. Purity >98%.
|
| References |
[1]. Rödström KE, et al. Structure of the superantigen staphylococcal enterotoxin B in complex with TCR and peptide-MHC demonstrates absence of TCR-peptide contacts. J Immunol. 2014 Aug 15;193(4):1998-2004.
[2]. Shupp JW, et al. Identification of a transcytosis epitope on staphylococcal enterotoxins. Infect Immun. 2002 Apr;70(4):2178-86. |
| Additional Infomation |
SEB Domain (152-161) TFA is a research peptide tool for studying staphylococcal enterotoxin biology and for developing therapeutic strategies against S. aureus toxin-mediated diseases. The peptide corresponds to a highly conserved domain on SEB that is essential for transcytosis. It has not entered clinical trials or received regulatory approval for human use. Sequence: KKKVTAQELD (TFA salt). Store at -20degC under nitrogen, away from light and moisture.
|
| Molecular Formula |
C52H91F3N14O19
|
|---|---|
| Related CAS # |
SEB Domain (152-161);210229-94-0
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (~39.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (78.53 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
